Eloxx Pharmaceuticals, Inc. (ELOX) - Net Assets
Based on the latest financial reports, Eloxx Pharmaceuticals, Inc. (ELOX) has net assets worth $46.42 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($63.39 Million) and total liabilities ($16.97 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See debt-free asset ratio of Eloxx Pharmaceuticals, Inc. to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $46.42 Million |
| % of Total Assets | 73.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Eloxx Pharmaceuticals, Inc. - Net Assets Trend (2022–2025)
This chart illustrates how Eloxx Pharmaceuticals, Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Eloxx Pharmaceuticals, Inc. (ELOX) total market value.
Annual Net Assets for Eloxx Pharmaceuticals, Inc. (2022–2025)
The table below shows the annual net assets of Eloxx Pharmaceuticals, Inc. from 2022 to 2025. Also explore net asset momentum of Eloxx Pharmaceuticals, Inc. to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-11.91 Million | +51.07% |
| 2024-12-31 | $-24.34 Million | -7.68% |
| 2023-12-31 | $-22.60 Million | -112.00% |
| 2022-12-31 | $-10.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eloxx Pharmaceuticals, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2619200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00K | % |
| Other Components | $288.62 Million | % |
| Total Equity | $-11.91 Million | 100.00% |
Eloxx Pharmaceuticals, Inc. Competitors by Market Cap
The table below lists competitors of Eloxx Pharmaceuticals, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Versatile Creative Bhd
KLSE:4995
|
$56.96 Million |
|
Mount Logan Capital Inc
NEO:MLC
|
$57.00 Million |
|
Lingotes
MC:LGT
|
$57.00 Million |
|
Petra Diamonds Ltd
LSE:PDL
|
$57.02 Million |
|
Galway Metals Inc.
V:GWM
|
$56.92 Million |
|
Beforepay Group Ltd
AU:B4P
|
$56.90 Million |
|
Yukselen Celik As
IS:YKSLN
|
$56.89 Million |
|
Koryo Electronics Co Ltd
TWO:8032
|
$56.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eloxx Pharmaceuticals, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -24,335,000 to -11,907,000, a change of 12,428,000.
- Net loss of 5,995,000 reduced equity.
- Other factors increased equity by 18,423,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.00 Million | -50.35% |
| Other Changes | $18.42 Million | +154.72% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Eloxx Pharmaceuticals, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-54.13 | $18.25 | x |
| 2023-12-31 | $-96.70 | $18.25 | x |
| 2024-12-31 | $-71.22 | $18.25 | x |
| 2025-12-31 | $-10.61 | $18.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eloxx Pharmaceuticals, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.00 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.79 Million |
| 2024 | 0.00% | -49.43% | 2.14x | 0.00x | $-709.50K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.80 Million |
Industry Comparison
This section compares Eloxx Pharmaceuticals, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | $46.42 Million | 0.00% | 0.37x | $56.94 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney dis… Read more